Cytochrome P450 and P-Glycoprotein-mediated interactions involving African herbs indicated for Common Noncommunicable Diseases

Evidence-based Complementary and Alternative Medicine

Volumn 2017, Issue , 2017, Pages

  Ondieki, Gregory ^a   Nyagblordzro, Makafui ^a   Kikete, Siambi ^a   Liang, Rongjia ^a   Wang, Lili ^a   He, Xin ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATHARANTHUS ROSEUS EXTRACT; CYTOCHROME P450; HERBACEOUS AGENT; MULTIDRUG RESISTANCE PROTEIN;

ACOKANTHERA OPPOSITIFOLIA; AFRICA; ANNONA SENEGALENSIS; ARTEMISIA; BLACK CUMIN; CATHARANTHUS ROSEUS; COMORBIDITY; DIABETES MELLITUS; DRUG METABOLISM; EUPHORBIA TUCKEYANA; FENUGREEK; HERB; HIBISCUS SABDARIFFA; HYPERTENSION; HYPOXIS HEMEROCALLIDEA; KALANCHOE; LEPIDIUM SATIVUM; MALIGNANT NEOPLASM; MANGO; NON COMMUNICABLE DISEASE; PHYLLANTHUS AMARUS; PREVALENCE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PYCNANTHUS ANGOLENSIS; REVIEW; SUTHERLANDIA FRUTESCENS;

EID: 85013489160     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2017/2582463     Document Type: Review

References (213)

1. R. Hermann and O. Von Richter, "Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions, " Planta Medica, vol. 78, no. 13, pp. 1458-1477, 2012.
2. M. Ekor, "The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety, " Frontiers in Pharmacology, vol. 4, article 177, 2014.
3. G.M. Cragg and D. J.Newman, "Natural products: a continuing source of novel drug leads, " Biochimica et Biophysica Acta- General Subjects, vol. 1830, no. 6, pp. 3670-3695, 2013.
4. WHO, Legal Status of Traditional Medicine and Complementar, 2001.
5. G. Y. Yeh, R. B. Davis, and R. S.Phillips, "Use of complementary therapies in patients with cardiovascular disease, " TheAmerican Journal of Cardiology, vol. 98, no. 5, pp. 673-680, 2006.
6. B.-E. Van Wyk, H. de Wet, and F. R. Van Heerden, "An ethnobotanical survey of medicinal plants in the southeastern Karoo, South Africa, " South African Journal of Botany, vol. 74, no. 4, pp. 696-704, 2008.
7. S. Bent, "Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center, " Journal of General Internal Medicine, vol. 23, no. 6, pp. 854-859, 2008.
8. A. O. Ogbera, O. Dada, F. Adeleye, and P. I. Jewo, "Complementary and alternativemedicine use in diabetes mellitus, " West African Journal of Medicine, vol. 29, no. 3, pp. 158-162, 2010.
9. O. C. Amira and N. U. Okubadejo, "Frequency of complementary and alternative medicine utilization in hypertensive patients attending an urban tertiary care centre in Nigeria, " BMC Complementary andAlternativeMedicine, vol. 7, article 30, 2007.
10. E. R. Ezeome and A. N. Anarado, "Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria, " BMC Complementary and Alternative Medicine, vol. 7, no. 1, article 28, 2007.
11. R. Nowack, "Review Article: Cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort-and beyond! (Review Article), " Nephrology, vol. 13, no. 4, pp. 337- 347, 2008.
12. A. A. Izzo and E. Ernst, "Interactions between herbalmedicines and prescribed drugs, " Drugs, vol. 69, no. 13, pp. 1777-1798, 2009.
13. B. J. Gurley, E. K. Fifer, and Z. Gardner, "Pharmacokinetic herbdrug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance, " Planta Medica, vol. 78, no. 13, pp. 1490-1514, 2012.
14. S. J. Brantley, T. N. Graf, N. H. Oberlies, and M. F. Paine, "A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors, " Drug Metabolism and Disposition, vol. 41, no. 9, pp. 1662-1670, 2013.
15. S.-B. Kim, I.-S. Yoon, K.-S. Kim et al., "In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome P450-mediated drug metabolism, " Planta Medica, vol. 80, no. 7, pp. 561-567, 2014.
16. I. Meijerman, J. H. Beijnen, and J. H. M. Schellens, "Herb-drug interactions in oncology: focus on mechanisms of induction, " The Oncologist, vol. 11, no. 7, pp. 742-752, 2006.
17. P. Gardiner, R. E. Graham, A. T. R. Legedza, D. M. Eisenberg, and R. S. Phillips, "Factors associated with dietary supplement use among prescription medication users, " Archives of Internal Medicine, vol. 166, no. 18, pp. 1968-1974, 2006.
18. J. Kennedy, C.-C. Wang, and C.-H. Wu, "Patient disclosure about herb and supplement use among adults in the US, " Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 4, pp. 451-456, 2008.
19. C. Tarirai, A. M. Viljoen, and J. H. Hamman, "Herb-drug pharmacokinetic interactions reviewed, " Expert Opinion on DrugMetabolism&Toxicology, vol. 6, no. 12, pp. 1515-1538, 2010.
20. L. Brown, O. Heyneke, D. Brown, J. P. H. van Wyk, and J. H. Hamman, "Impact of traditional medicinal plant extracts on antiretroviral drug absorption, " Journal of Ethnopharmacology, vol. 119, no. 3, pp. 588-592, 2008.
21. H. Tunstall-Pedoe, "Preventing chronic diseases. A vital investment: WHOglobal report.Geneva:WorldHealthOrganization, 2005. pp 200. CHF 30.00. ISBN 92 4 1563001, " International Journal of Epidemiology, vol. 35, no. 4, p. 1107, 2006.
22. G. Danaei, S. V. Hoorn, A. D. Lopez, C. J. L. Murray, and M. Ezzati, "Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors, " The Lancet, vol. 366, no. 9499, pp. 1784-1793, 2005.
23. D. H. Roukos, "Genome-wide association studies: how predictable is a person's cancer risk?" Expert Review of Anticancer Therapy, vol. 9, no. 4, pp. 389-392, 2009.
24. J. S. Oliver, "United States, Africa, Caribbean collaboration: strengths and opportunities for global cancer research, " in Proceedings of the SigmaTheta Tau International's 27th International Nursing Research Congress (STTI '16), Utrecht, TheNetherlands, 2016.
25. M. A. Weber, E. L. Schiffrin, W. B. White et al., "Clinical practice guidelines for the management of hypertension in the community, "The Journal of Clinical Hypertension, vol. 16, no. 1, pp. 14-26, 2014.
26. D.Bradshaw, P. Groenewald, R. Laubscher et al., "Initial burden of disease estimates for South Africa, 2000, " South African Medical Journal, vol. 93, no. 9, pp. 682-688, 2003.
27. A. P. Kengne and B. M. Mayosi, "Readiness of the primary care system for non-communicable diseases in sub-Saharan Africa, " The Lancet Global Health, vol. 2, no. 5, pp. e247-e248, 2014.
28. C. J. Murray, T. Vos, and R. Lozano, "Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990- 2010: a systematic analysis for the Global Burden of Disease Study 2010, " The Lancet, vol. 380, no. 859, pp. 2197-2223, 2010.
29. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, "Global estimates of the prevalence of diabetes for 2010 and 2030, " Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4-14, 2010.
30. C. M. M. Lawes, S. Vander Hoorn, M. R. Law, P. Elliott, S. MacMahon, and A. Rodgers, "Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels, " Journal ofHypertension, vol. 24, no. 3, pp. 413-422, 2006.
31. WHO Regional Office for Africa, The Health of the People: The African Regional Health Report, World Health Organization, 2006.
32. B. M. Mayosi, "The 10 'Best Buys' to combat heart disease, diabetes and stroke in Africa, " Heart, vol. 99, no. 14, pp. 973- 974, 2013.
33. F. Bray, J.-S. Ren, E.Masuyer, and J. Ferlay, "Global estimates of cancer prevalence for 27 sites in the adult population in 2008, " International Journal of Cancer, vol. 132, no. 5, pp. 1133-1145, 2013.
34. L.A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, "Global cancer statistics, 2012, " CA Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87-108, 2015.
35. K. S. Ogle, G. M. Swanson, N. Woods, and F. Azzouz, "Cancer and comorbidity: redefining chronic diseases, " Cancer, vol. 88, no. 3, pp. 653-663, 2000.
36. A.M.Gerber, R. Botes, A. Mostert, A. Vorster, and E. Buskens, "A cohort study of elderly people in Bloemfontein, South Africa, to determine health-related quality of life and functional abilities, " South AfricanMedical Journal, vol. 106, no. 3, pp. 298- 301, 2016.
37. N. Folb, V. Timmerman, N. S. Levitt et al., "Multimorbidity, control and treatment of noncommunicable diseases among primary healthcare attenders in the Western Cape, South Africa, " South African Medical Journal, vol. 105, no. 8, pp. 642- 647, 2015.
38. S. Zhou, Y. Gao, W. Jiang, M. Huang, A. Xu, and J. W. Paxton, "Interactions of herbs with cytochrome P450, " DrugMetabolism Reviews, vol. 35, no. 1, pp. 35-98, 2003.
39. D. E. Amacher, "The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies, " ToxicologyMechanisms andMethods, vol. 20, no. 4, pp. 159-166, 2010.
40. S. Rendic and F. J. Di Carlo, "Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors, " DrugMetabolismReviews, vol. 29, no. 1-2, pp. 413-580, 1997.
41. J.-J. Wu, C.-Z. Ai, Y. Liu et al., "Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes, " Current Drug Metabolism, vol. 13, no. 5, pp. 599-614, 2012.
42. H. Zhang, D. Cui, B. Wang et al., "Pharmacokinetic drug interactions involving 17-ethinylestradiol: a new look at an old drug, " Clinical Pharmacokinetics, vol. 46, no. 2, pp. 133-157, 2007.
43. O. Pelkonen, M. Turpeinen, J. Hakkola, P. Honkakoski, J. Hukkanen, and H. Raunio, "Inhibition and induction of human cytochrome P450 enzymes: current status, " Archives of Toxicology, vol. 82, no. 10, pp. 667-715, 2008.
44. P. B. Watkins, S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S. Guzelian, "Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, " The Journal of Clinical Investigation, vol. 80, no. 4, pp. 1029-1036, 1987.
45. A. H. Schinkel and J. W. Jonker, "Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview, " Advanced Drug Delivery Reviews, vol. 55, no. 1, pp. 3-29, 2003.
46. Y. Romsicki and F. J. Sharom, "The ATPase and ATP-binding functions of P-glycoprotein, " European Journal of Biochemistry, vol. 256, no. 1, pp. 170-178, 1998.
47. M. M. R. De Maat, G. Corine Ekhart, A. D. R. Huitema, C. H. W. Koks, J. W. Mulder, and J. H. Beijnen, "Drug interactions between antiretroviral drugs and comedicated agents, " Clinical Pharmacokinetics, vol. 42, no. 3, pp. 223-282, 2003.
48. S.-F. Zhou, "Structure, function and regulation of Pglycoprotein and its clinical relevance in drug disposition, " Xenobiotica, vol. 38, no. 7-8, pp. 802-832, 2008.
49. M.Takano, R.Yumoto, and T.Murakami, "Expression and function of efflux drug transporters in the intestine, " Pharmacology andTherapeutics, vol. 109, no. 1-2, pp. 137-161, 2006.
50. S. Katragadda, B. Budda, B. S. Anand, and A. K. Mitra, "Role of efflux pumps and metabolising enzymes in drug delivery, " Expert Opinion on Drug Delivery, vol. 2, no. 4, pp. 683-705, 2005.
51. S. B. Syed and M. S. Coumar, "P-glycoprotein mediated multidrug resistance reversal by phytochemicals: a review of SAR & future perspective for drug design, " Current Topics inMedicinal Chemistry, vol. 16, no. 22, pp. 2484-2508, 2016.
52. S. Zhou, L. Y. Lim, and B. Chowbay, "Herbal modulation of P-glycoprotein, " Drug Metabolism Reviews, vol. 36, no. 1, pp. 57-104, 2004.
53. J. Hunter and B. H. Hirst, "Intestinal secretion of drugs. The role of P-glycoprotein and related drugefflux systems in limiting oral drug absorption, " Advanced Drug Delivery Reviews, vol. 25, no. 2-3, pp. 129-157, 1997.
54. S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens, "Concise review: clinical relevance of drug-drug and herb- drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein), " Oncologist, vol. 12, no. 8, pp. 927-941, 2007.
55. S. Gupta, "P-glycoprotein expression and regulation: agerelated changes and potential effects on drug therapy, " Drugs & Aging, vol. 7, no. 1, pp. 19-29, 1995.
56. S. Gollapudi, M. Reddy, P. Gangadharam, T. Tsuruo, and S. Gupta, "Mycobacterium tuberculosis induces expression of Pglycoprotein in promonocytic U1 cells chronically infected with HIV type 1, " Biochemical and Biophysical Research Communications, vol. 199, no. 3, pp. 1181-1187, 1994.
57. A. Ahmadu, A. Abdulkarim, R. Grougnet et al., "Two new peltogynoids from Acacia nilotica Delile with kinase inhibitory activity, " Planta Medica, vol. 76, no. 5, pp. 458-460, 2010.
58. R. Singh, B. Singh, S. Singh, N. Kumar, S. Kumar, and S. Arora, "Anti-free radical activities of kaempferol isolated from Acacia nilotica (L.) Willd. Ex. Del., " Toxicology in Vitro, vol. 22, no. 8, pp. 1965-1970, 2008.
59. S. Deferme, A. Kamuhabwa, C. Nshimo, P. De Wittez, and P. Augustijns, "Screening of Tanzanian plant extracts for their potential inhibitory effect on P-glycoprotein mediated efflux, " Phytotherapy Research, vol. 17, no. 5, pp. 459-464, 2003.
60. A. Agbonon, K. Eklu-Gadegbeku, K. Aklikokou et al., "In vitro inhibitory effect of West African medicinal and food plants on human cytochrome P450 3A subfamily, " Journal of Ethnopharmacology, vol. 128, no. 2, pp. 390-394, 2010.
61. E. O. Ajaiyeoba and O. Ekundayo, "Essential oil constituents of Aframomum melegueta (Roscoe) K. Schum. seeds (alligator pepper) from Nigeria, " Flavour and Fragrance Journal, vol. 14, no. 2, pp. 109-111, 1999.
62. R. M. P. Gutierrez, E. G. Baez, M. del Socorro Ĺopez Cortez, andS. A. Ćardenas, "Extracts of bixa inhibit glycation andAGEs formation in vitro, " Journal of Medicinal Plants Research, vol. 5, no. 6, pp. 942-948, 2011.
63. C. Jewell and N.M. O'Brien, "Effect of dietary supplementation with carotenoids on xenobiotic metabolizing enzymes in the liver, lung, kidney and small intestine of the rat, " British Journal of Nutrition, vol. 81, no. 3, pp. 235-242, 1999.
64. T. Nabekura, S. Kamiyama, and S. Kitagawa, "Effects of dietary chemopreventive phytochemicals on P-glycoprotein function, " Biochemical and Biophysical Research Communications, vol. 327, no. 3, pp. 866-870, 2005.
65. E. F. Oga, S. Sekine, Y. Shitara, and T. Horie, "P-glycoprotein mediated efflux in Caco-2 cell monolayers: The influence of herbals on digoxin transport, " Journal of Ethnopharmacology, vol. 144, no. 3, pp. 612-617, 2012.
66. M. Rodrigues, G. Alves, J. Francisco, A. Fortuna, and A. Falcao, "Herb-drug pharmacokinetic interaction between carica papaya extract and amiodarone in rats, " Journal of Pharmacy and Pharmaceutical Sciences, vol. 17, no. 3, pp. 302-315, 2014.
67. L.Tona, K. Kambu, N. Ngimbi, K.Cimanga, and A. J. Vlietinck, "Antiamoebic and phytochemical screening of some Congolese medicinal plants, " Journal of Ethnopharmacology, vol. 61, no. 1, pp. 57-65, 1998.
68. N. M. Piero, M. N. Joan, K. M. Cromwell et al., "Hypoglycemic activity of some kenyan plants traditionally used to manage diabetes mellitus in eastern province, " Journal of Diabetes & Metabolism, vol. 2, article 8, 2011.
69. W. Bedada, F. De Andŕes, E. Engidawork et al., "The psychostimulant khat (Catha edulis) inhibits CYP2D6 enzyme activity in humans, " Journal of Clinical Psychopharmacology, vol. 35, no. 6, pp. 694-699, 2015.
70. J. Savai, A. Varghese, N. Pandita, and M. Chintamaneni, "Investigation of CYP3A4 and CYP2D6 interactions of Withania somnifera and centella asiatica in human liver microsomes, " Phytotherapy Research, vol. 29, no. 5, pp. 785-790, 2015.
71. Y. Pan, B. A. Abd-Rashid, Z. Ismail et al., "In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica, " Journal of Ethnopharmacology, vol. 130, no. 2, pp. 275-283, 2010.
72. N. M. M. Shalaby, H. I. Abd-Alla, H. H. Ahmed, and N. Basoudan, "Protective effect of Citrus sinensis and Citrus aurantifolia against osteoporosis and their phytochemical constituents, " Journal of Medicinal Plants Research, vol. 5, no. 4, pp. 579-588, 2011.
73. J.Cao, L. Zheng, L. Ji, D. Lu, Y. Peng, and J. Zheng, "Mechanismbased inactivation of cytochrome P450 2B6 by isoimperatorin, " Chemico-Biological Interactions, vol. 226, pp. 23-29, 2015.
74. S.Malhotra, D. G. Bailey, M. F. Paine, and P. B.Watkins, "Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins, " Clinical Pharmacology &Therapeutics, vol. 69, no. 1, pp. 14-23, 2001.
75. H. Takanaga, A. Ohnishi, S. Yamada et al., "Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4, " Journal of Pharmacology and Experimental Therapeutics, vol. 293, no. 1, pp. 230-236, 2000.
76. T. Nabekura, T. Yamaki, and S. Kitagawa, "Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1, " European Journal of Pharmacology, vol. 600, no. 1-3, pp. 45-49, 2008.
77. K. Azuma, M. Nakayama, M. Koshioka et al., "Phenolic antioxidants from the leaves of Corchorus olitorius L., " Journal of Agricultural and Food Chemistry, vol. 47, no. 10, pp. 3963-3966, 1999.
78. S. Nwozo, O. Adaramoye, and E. Ajaiyeoba, "Oral administration of extract from Curcuma longa lowers blood glucose and attenuates alloxan-induced hyperlipidemia in diabetic rabbits, " Pakistan Journal of Nutrition, vol. 8, no. 5, pp. 625-628, 2009.
79. P. Neerati, R. Karan, and J. R. Kanwar, "Influence of curcumin on pioglitazone metabolism and Pk/Pd: diabetes mellitus, " Journal of Diabetes & Metabolism, vol. 1, no. S6, 2013.
80. R. Appiah-Opong, J. N. M. Commandeur, B. van Vugt- Lussenburg, and N. P. E. Vermeulen, "Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products, " Toxicology, vol. 235, no. 1-2, pp. 83- 91, 2007.
81. Y. Chen, W.-H. Liu, B.-L. Chen et al., "Plant polyphenol curcumin significantly affects CYPIA2 and CYP2A6 activity in healthy, male Chinese volunteers, " Annals of Pharmacotherapy, vol. 44, no. 6, pp. 1038-1045, 2010.
82. C. Ampasavate, U. Sotanaphun, P. Phattanawasin, and N. Piyapolrungroj, "Effects of Curcuma spp. on P-glycoprotein function, " Phytomedicine, vol. 17, no. 7, pp. 506-512, 2010.
83. H. A. Abdelgadir and J. Van Staden, "Ethnobotany, ethnopharmacology and toxicity of Jatropha curcas L. (Euphorbiaceae): a review, " South African Journal of Botany, vol. 88, pp. 204-218, 2013.
84. J. M. Dalziel, The useful plants of west tropical Africa, The useful plants ofWest Tropical Africa, 1937.
85. A. C. Adebajo and J. Reisch, "Minor furocoumarins ofMurraya koenigii, " Fitoterapia, vol. 71, no. 3, pp. 334-337, 2000.
86. A. C. Adebajo, G. Olayiwola, J. E. Verspohl et al., "Evaluation of the ethnomedical claims of Murraya koenigii, " Pharmaceutical Biology, vol. 42, no. 8, pp. 610-620, 2004.
87. S. Pandit, P. K. Mukherjee, K. Mukherjee et al., "Cytochrome P450 inhibitory potential of selected Indian spices-possible food drug interaction, " Food Research International, vol. 45, no. 1, pp. 69-74, 2012.
88. A. O. Ogunbinu, I. A. Ogunwande, G. Flamini, and P. L. Cioni, "Volatile compounds of Persea americana Mill from Nigeria, " Journal of Essential Oil-Bearing Plants, vol. 10, no. 2, pp. 133-138, 2007.
89. T. Nabekura, T. Yamaki, K. Ueno, and S. Kitagawa, "Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals, " Cancer Chemotherapy and Pharmacology, vol. 62, no. 5, pp. 867-873, 2008.
90. O. O. Babalola, J. I. Anetor, and F. A. Adeniyi, "Amelioration of carbon tetrachloride-induced hepatotoxicity by terpenoid extract from leaves of Vernonia amydgalina, " African Journal of Medicine and Medical Sciences, vol. 30, no. 1-2, pp. 91-93, 2001.
91. S. Skalli, A. Zaid, and R. Soulaymani, "Drug interactions with herbal medicines, " Therapeutic Drug Monitoring, vol. 29, no. 6, pp. 679-686, 2007.
92. W. Cordier and V. Steenkamp, "Drug interactions in African herbal remedies, " Drug Metabolism and Drug Interactions, vol. 26, no. 2, pp. 53-63, 2011.
93. P.Zimmet, K. G.M.M. Alberti, and J.Shaw, "Global and societal implications of the diabetes epidemic, " Nature, vol. 414, no. 6865, pp. 782-787, 2001.
94. WHO, World Health Organization Fact Sheet Number 312, World Health Organization, Geneva, Switzerland, 2006.
95. L. L. Brunton, B. Chabner, and B. C. Knollmann, Goodman & Gilman's the Pharmacological Basis of Therapeutics, vol. 12, McGraw-Hill Medical, New York, NY, USA, 2011.
96. G. C. Mannino and G. Sesti, "Individualized therapy for type 2 diabetes, " Molecular Diagnosis & Therapy, vol. 16, no. 5, pp. 285-302, 2012.
97. M. Al-Habori and A. Raman, "Antidiabetic and hypocholesterolaemic effects of fenugreek, " Phytotherapy Research, vol. 12, no. 4, pp. 233-242, 1998.
98. G. Y. Yeh, D. M. Eisenberg, T. J. Kaptchuk, and R. S. Phillips, "Systematic review of herbs and dietary supplements for glycemic control in diabetes, " Diabetes Care, vol. 26, no. 4, pp. 1277-1294, 2003.
99. M. Shang, S. Cai, and X. Wang, "Analysis of amino acids in Trigonella foenumgraecumseeds, " Journal of Chinese medicinal materials, vol. 21, no. 4, pp. 188-190, 1998.
100. B. Bin-Hafeez, R. Haque, S. Parvez, S. Pandey, I. Sayeed, and S. Raisuddin, "Immunomodulatory effects of fenugreek (Trigonella foenum graecum L.) extract in mice, " International Immunopharmacology, vol. 3, no. 2, pp. 257-265, 2003.
101. T. Zia, S. N. Hasnain, and S. K. Hasan, "Evaluation of the oral hypoglycaemic effect of Trigonella foenum-graecum L. (methi) in normal mice, " Journal of Ethnopharmacology, vol. 75, no. 2-3, pp. 191-195, 2001.
102. F. Al-Jenoobi, H. M. Korashy, A. Ahad et al., "Potential inhibitory effect of herbalmedicines on rat hepatic cytochrome P450 2D gene expression and metabolic activity, " Die Pharmazie, vol. 69, no. 11, pp. 799-803, 2014.
103. F. I. Al-Jenoobi, A. A. Al-Thukair, M. A. Alam et al., "Effect of Trigonella foenum-graecum L. onMetabolicActivity ofCYP2D6 and CYP3A4, " Forschende Komplementarmedizin, vol. 22, no. 3, pp. 180-184, 2015.
104. H.M. Korashy, F. I. Al-Jenoobi, M.Raish et al., "Impactofherbal medicines like nigella sativa, trigonella foenum-graecum, and ferula asafoetida, on cytochrome P450 2C11 gene expression in rat liver, " Drug Research, vol. 65, no. 7, pp. 366-372, 2014.
105. M. F. Al-Ajmi, "The effect of fenugreek on the bioavailability of glibenclamide in normal beagle dogs, " African Journal of Pharmacy and Pharmacology, vol. 5, no. 6, pp. 671-677, 2011.
106. V. K. Manda, B. Avula, Z. Ali et al., "Characterization of in vitro ADME properties of diosgenin and dioscin from Dioscorea villosa, " Planta Medica, vol. 79, no. 15, pp. 1421-1428, 2013.
107. E. Adjanohoun, "Traditional medicine and pharmacopoeia: contribution to ethnobotanical and floristic studies in Cameroon, " Tech. Rep., Scientific, Technical, and Research Commission of the Organization of African Unity, Lagos, Nigeria, 1996.
108. R. Kamgang, R. Youmbi Mboumi, A. Foyet Fondjo, M. A. Fokam Tagne, G. P. R. Mengue N'dilĺe, and J. Ngogang Yonkeu, "Antihyperglycaemic potential of the water-ethanol extract of Kalanchoe crenata (Crassulaceae), " Journal of Natural Medicines, vol. 62, no. 1, pp. 34-40, 2008.
109. C. Awortwe, V. K. Manda, C. Avonto et al., "In vitro evaluation of reversible and time-dependent inhibitory effects of kalanchoe crenata on CYP2C19 and CYP3A4 activities, " Drug Metabolism Letters, vol. 9, no. 1, pp. 48-62, 2015.
110. M. A. Khan, "Chemical composition and medicinal properties of Nigella sativa Linn., " Inflammopharmacology, vol. 7, no. 1, pp. 15-35, 1999.
111. A.-U. H. Gilani, Q. Jabeen, and M. A. U. Khan, "A review of medicinal uses and pharmacological activities of Nigella sativa, " Pakistan Journal of Biological Sciences, vol. 7, no. 4, pp. 441-451, 2004.
112. A. Al-Hader, M. Aqel, and Z. Hasan, "Hypoglycemic effects of the volatile oil of Nigella sativa seeds, " International Journal of Pharmacognosy, vol. 31, no. 2, pp. 96-100, 1993.
113. B.Meddah, R. Ducroc, M. El Abbes Faouzi et al., "Nigella sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats, " Journal of Ethnopharmacology, vol. 121, no. 3, pp. 419-424, 2009.
114. F. I. Al-Jenoobi, A. A. Al-Thukair, F. A. Abbas et al., "Effect of black seed on dextromethorphan O- And N-demethylation in human liver microsomes and healthy human subjects, " Drug Metabolism Letters, vol. 4, no. 1, pp. 51-55, 2010.
115. F. I. Al-Jenoobi, S. A. Al-Suwayeh, I. Muzaffar et al., "Effects of Nigella sativa and Lepidium sativum on cyclosporine pharmacokinetics, " BioMed Research International, vol. 2013, Article ID 953520, 6 pages, 2013.
116. U. K. Mazunder, M. Gupta, and Y. Rajeshwar, "Antihyperglycemic effect and antioxidant potential of Phyllanthus niruri (Euphorbiaceae) in streptozotocin induced diabetic rats, " European Bulletin of Drug Research, vol. 13, no. 1, pp. 15-23, 2005.
117. L. Taylor, Herbal Secret of Rainforest, Sagca Press, 2nd edition, 2003.
118. G. Bagalkotkar, S. R. Sagineedu, M. S. Saad, and J. Stanslas, "Phytochemicals from Phyllanthus niruri Linn. and their pharmacological properties: a review, " Journal of Pharmacy and Pharmacology, vol. 58, no. 12, pp. 1559-1570, 2006.
119. R. Appiah-Opong, J. N. M. Commandeur, C. Axson, and N. P. E. Vermeulen, "Interactions between cytochromes P450, glutathione S-transferases and Ghanaian medicinal plants, " Food and Chemical Toxicology, vol. 46, no. 12, pp. 3598-3603, 2008.
120. T. Taesotikul, W. Dumrongsakulchai, N. Wattanachai et al., "Inhibitory effects of phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition, " Drug Metabolism and Pharmacokinetics, vol. 26, no. 2, pp. 154-161, 2011.
121. M.Wongnawa, P. Kaewmeesri, S. Sriwiriyajan, W.Mahatthanatrakul, and W. Ridtitid, "Effect of Phyllanthus amarus extract on the pharmacokinetics of midazolamin rabbits, " Songklanakarin Journal of Science&Technology, vol. 36, no. 5, pp. 547-553, 2014.
122. T. Taesotikul, M. Nakajima, W. Tassaneeyakul, and T. Yokoi, "Effects of Phyllanthus amarus on the pharmacokinetics of midazolamand cytochromeP450 activities in rats, " Xenobiotica, vol. 42, no. 7, pp. 641-648, 2012.
123. M. Eddouks, M.Maghrani, A. Lemhadri, M.-L.Ouahidi, and H. Jouad, "Ethnopharmacological survey of medicinal plants used for the treatment of diabetesmellitus, hypertension and cardiac diseases in the south-east region ofMorocco (Tafilalet), " Journal of Ethnopharmacology, vol. 82, no. 2-3, pp. 97-103, 2002.
124. M. Zia-Ul-Haq, S. Ahmad, L. Calani et al., "Compositional study and antioxidant potential of Ipomoea hederacea Jacq. and Lepidium sativum L. seeds, " Molecules, vol. 17, no. 9, pp. 10306- 10321, 2012.
125. M. Eddouks and M. Maghrani, "Effect of Lepidium sativum L. on renal glucose reabsorption and urinary TGF-1 levels in diabetic rats, " Phytotherapy Research, vol. 22, no. 1, pp. 1-5, 2008.
126. F. I. Al-Jenoobi, A. A. Al-Thukair, M. A. Alam et al., "Effect of garden cress seeds powder and its alcoholic extract on the metabolic activity of CYP2D6 and CYP3A4, " Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 634592, 6 pages, 2014.
127. B. Higgins and B. Williams, "Pharmacologicalmanagement of hypertension, " ClinicalMedicine, vol. 7, no. 6, pp. 612-616, 2007.
128. L. J. Beilin, "Non-pharmacological management of hypertension: optimal strategies for reducing cardiovascular risk, " Journal of Hypertension, vol. 12, no. 10, pp. S71-S81, 1994.
129. GRIN, Artemisia herba-alba Asso Taxonomy for Plants, Grin Global, 2010.
130. R. Segal, I. Feuerstein, and A.Danin, "Chemotypes of Artemisia herba-alba in Israel based on their sesquiterpene lactone and essential oil constitution, " Biochemical Systematics and Ecology, vol. 15, no. 4, pp. 411-416, 1987.
131. A. Tahraoui, J. El-Hilaly, Z. H. Israili, and B. Lyoussi, "Ethnopharmacological survey of plants used in the traditional treatment of hypertension and diabetes in south-eastern Morocco (Errachidia province), " Journal of Ethnopharmacology, vol. 110, no. 1, pp. 105-117, 2007.
132. N.-A. Zeggwagh, O. Farid, J. B. Michel, and M. Eddouks, "Cardiovascular effect of Artemisia herba alba aqueous extract in spontaneously hypertensive rats, " Methods and Findings in Experimental and Clinical Pharmacology, vol. 30, no. 5, pp. 375- 381, 2008.
133. A. E.-H. H. Mohamed, M. A. El-Sayed, M. E. Hegazy, S. E. Helaly, A. M. Esmail, and N. S. Mohamed, "Chemical constituents and biological activities of Artemisia herba-alba, " Records of Natural Products, vol. 4, no. 1, pp. 1-25, 2010.
134. A.-H. Mohamed, A. M. Esmail, and A. M. El-Saade, "Terpenes from Artemisia herba-alba, " Zeitschrift fur Naturforschung C, vol. 68, no. 9-10, pp. 343-346, 2013.
135. M. Laid, M.-E. F. Hegazy, A. A. Ahmed, K. Ali, D. Belkacemi, and S. Ohta, "Sesquiterpene lactones from Algerian Artemisia herba-alba, " Phytochemistry Letters, vol. 1, no.2, pp. 85-88, 2008.
136. A. Moufid and M. Eddouks, "Artemisia herba alba: a popular plant with potential medicinal properties, " Pakistan Journal of Biological Sciences, vol. 15, no. 24, pp. 1152-1159, 2012.
137. S. Zouari, N. Zouari, N. Fakhfakh, A. Bougatef, M. A. Ayadi, and M. Neffati, "Chemical composition and biological activities of a new essential oil chemotype of Tunisian Artemisia herba alba Asso, " Journal of Medicinal Plants Research, vol. 4, no. 10, pp. 871-880, 2010.
138. C.Ulbricht, W. Chao, D. Costa, E. Rusie-Seamon, W. Weissner, and J. Woods, "Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration, " Current Drug Metabolism, vol. 9, no. 10, pp. 1063-1120, 2008.
139. D.Khlifi, R. M. Sghaier, S.Amouri, D. Laouini, M.Hamdi, and J. Bouajila, "Composition and anti-oxidant, anti-cancer and antiinflammatory activities of Artemisia herba-alba, Ruta chalpensis L. and Peganumharmala L., " Food and Chemical Toxicology, vol. 55, pp. 202-208, 2013.
140. O. Pelkonen, K. Abass, and J. Wiesner, "Thujone and thujonecontaining herbalmedicinal and botanical products: Toxicological assessment, " Regulatory Toxicology and Pharmacology, vol. 65, no. 1, pp. 100-107, 2013.
141. H. A. Wahabi, L.A.Alansary, A. H. Al-Sabban, and P.Glasziuo, "The effectiveness of Hibiscus sabdariffa in the treatment of hypertension: a systematic review, " Phytomedicine, vol. 17, no. 2, pp. 83-86, 2010.
142. M. H. Faraji and A. H. H. Tarkhani, "The effect of sour tea (Hibiscus sabdariffa) on essential hypertension, " Journal of Ethnopharmacology, vol. 65, no. 3, pp. 231-236, 1999.
143. A.Herrera-Arellano, S. Flores-Romero, M. A. Chavez-Soto, and J. Tortoriello, "Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial, " Phytomedicine, vol. 11, no. 5, pp. 375-382, 2004.
144. O. O. Ndu, C. S. Nworu, C. O. Ehiemere, N. C. Ndukwe, and I. S. Ochiogu, "Herb-drug interaction between the extract of Hibiscus sabdariffa L. and hydrochlorothiazide in experimental animals, " Journal of Medicinal Food, vol. 14, no. 6, pp. 640-644, 2011.
145. S. S. Johnson, F. T. Oyelola, T. Ari, and H. Juho, "In vitro inhibitory activities of the extract of Hibiscus sabdariffa L. (family Malvaceae) on selected cytochrome P450 isoforms, " African journal of traditional, complementary, and alternative medicines, vol. 10, no. 3, pp. 533-540, 2013.
146. P. Prommetta, L. Phivthong-Ngam, C. Chaichantipyuth, N. Niwattisaiwong, and S. Lawanprasert, "Aqueous extract of the calyces of Hibiscus subdariffa Linn.: effects on hepatic cytochrome P450 and subacute toxicity in rats, " Thai Journal of Pharmaceutical Sciences, vol. 30, pp. 8-18, 2006.
147. H. M. Abdallah, A. M. Al-Abd, R. S. El-Dine, and A. M. El- Halawany, "P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review, " Journal of Advanced Research, vol. 6, no. 1, pp. 45-62, 2015.
148. M.M. Gottesman, T. Fojo, and S. E. Bates, "Multidrug resistance in cancer: role of ATP-dependent transporters, " Nature Reviews Cancer, vol. 2, no. 1, pp. 48-58, 2002.
149. G. Bradley and V. Ling, "P-glycoprotein, multidrug resistance and tumor progression, " Cancer andMetastasis Reviews, vol. 13, no. 2, pp. 223-233, 1994.
150. H.Thomas and H. M. Coley, "Overcomingmultidrug resistance in cancer: an update on the clinical strategy of inhibiting pglycoprotein, " Cancer Control, vol. 10, no. 2, pp. 159-165, 2003.
151. R. J. Kelly, D. Draper, C. C. Chen et al., "A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer, " Clinical Cancer Research, vol. 17, no. 3, pp. 569-580, 2011.
152. R. J. Kelly, R.W. Robey, C. C. Chen et al., "A pharmacodynamic study of the P-glycoprotein antagonist CBT-1- in combination with paclitaxel in solid tumors, " The Oncologist, vol. 17, no. 4, p. 512, 2012.
153. G. M. Cragg and D. J. Newman, "Plants as a source of anticancer agents, " Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 72-79, 2005.
154. J.-E. Kim, H.-J. Cho, J. S. Kim et al., "The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin, " Xenobiotica, vol. 43, no. 7, pp. 579-591, 2013.
155. M. A. Bisi-Johnson, C. L. Obi, T. Hattori et al., "Evaluation of the antibacterial and anticancer activities of some South African medicinal plants, " BMC Complementary and Alternative Medicine, vol. 11, no. 1, article 14, 2011.
156. M. E. M. Saeed, M.Meyer, A.Hussein, and T. Efferth, "Cytotoxicity of South-African medicinal plants towards sensitive and multidrug-resistant cancer cells, " Journal of Ethnopharmacology, vol. 186, pp. 209-223, 2016.
157. V. Steenkamp and M. C. Gouws, "Cytotoxicity of six South African medicinal plant extracts used in the treatment of cancer, " South African Journal of Botany, vol. 72, no. 4, pp. 630- 633, 2006.
158. W. S. El-Deiry, "Role of oncogenes in resistance and killing by cancer therapeutic agents, " Current Opinion in Oncology, vol. 9, no. 1, pp. 79-87, 1997.
159. 53-expressing cancer stem cells and drug resistance, " Carcinogenesis, vol. 35, no. 6, pp. 1196-1208, 2014.
160. M. C. Da Silva, S. Izidine, and A. B. Amude, A Preliminary Checklist of the Vascular Plants of Mozambique, Sabonet, 2004.
161. B.-E. Van Wyk, F. van Heerden, and B. van Oudtshoorn, Poisonous Plants of South Africa, Briza Publications, Pretoria, South Africa, 2002.
162. G. Fouche, G.M.Cragg, P. Pillay, N. Kolesnikova, V. J. Maharaj, and J. Senabe, "In vitro anticancer screening of South African plants, " Journal of Ethnopharmacology, vol. 119, no. 3, pp. 455- 461, 2008.
163. C. Riganti, I. Campia, J. Kopecka et al., "Pleiotropic effects of cardioactive glycosides, " Current Medicinal Chemistry, vol. 18, no. 6, pp. 872-885, 2011.
164. M. Zeino, M. S. Paulsen, M. Zehl, E. Urban, B. Kopp, and T. Efferth, "Identification of newP-glycoprotein inhibitors derived from cardiotonic steroids, " Biochemical Pharmacology, vol. 93, no. 1, pp. 11-24, 2015.
165. F. Brouillard, D. Tondelier, A. Edelman, and M. Baudouin- Legros, "Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells, " Cancer Research, vol. 61, no. 4, pp. 1693-1698, 2001.
166. M. S. Abubakar, A. M. Musa, A. Ahmed, and I. M. Hussaini, "The perception and practice of traditional medicine in the treatment of cancers and inflammations by the Hausa and Fulani tribes of Northern Nigeria, " Journal of Ethnopharmacology, vol. 111, no. 3, pp. 625-629, 2007.
167. E. Ajaiyeoba, M. Falade, O. Ogbole, L. Okpako, and D. Akinboye, Short Communication-In Vivo Antimalarial and Cytotoxic Properties of Annona Senegalensis Extract, African Ethnomedicines Network, 2006.
168. M. You, D. B. M. Wickramaratne, G. L. Silva et al., "(-)- Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells, " Journal of Natural Products, vol. 58, no. 4, pp. 598-604, 1995.
169. N. Duarte, A. Jardanhazy, J. Molńar, A. Hilgeroth, and M.-J. U. Ferreira, "Synergistic interaction between p-glycoprotein modulators and epirubicine on resistant cancer cells, " Bioorganic & Medicinal Chemistry, vol. 16, no. 20, pp. 9323-9330, 2008.
170. A. A. Adeneye, O. Awodele, S. A. Aiyeola, and A. S. Benebo, "Modulatory potentials of the aqueous stem bark extract of Mangifera indica on carbon tetrachloride-induced hepatotoxicity in rats, " Journal of Traditional and Complementary Medicine, vol. 5, no. 2, pp. 106-115, 2015.
171. J. Ojewole, "Antiinflammatory, analgesic and hypoglycemic effects of Mangifera indica Linn. (Anacardiaceae) stem-bark aqueous extract, " Methods and Findings in Experimental and Clinical Pharmacology, vol. 27, no. 8, pp. 547-554, 2005.
172. K. Shah, M. Patel, R. Patel, and P. Parmar, "Mangifera indica (mango), " Pharmacognosy Reviews, vol. 4, no. 7, pp. 42-48, 2010.
173. M. Louisa, T. M. Soediro, and F. D. Suyatna, "In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells, " Asian Pacific Journal of Cancer Prevention, vol. 15, no. 4, pp. 1639-1642, 2014.
174. I. Rodeiro, M. Jośe Ǵomez-Lechon, G. Perez et al., "Mangifera indica L. extract and mangiferin modulate cytochrome P450 and UDP-glucuronosyltransferase enzymes in primary cultures of human hepatocytes, " Phytotherapy Research, vol. 27, no. 5, pp. 745-752, 2013.
175. N. Duarte, H. Lage, M. Abrantes, and M.-J. U. Ferreira, "Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells, " PlantaMedica, vol. 76, no. 10, pp. 975-980, 2010.
176. T. A. Mansoor, R. M. Ramalho, C. M. P. Rodrigues, and M.-J. U. Ferreira, "Dibenzylbutane- And butyrolactone-type lignans as apoptosis inducers in human hepatomaHuH-7 cells, " Phytotherapy Research, vol. 26, no. 5, pp. 692-696, 2012.
177. B.-E. Van Wyk and C. Albrecht, "A review of the taxonomy, ethnobotany, chemistry and pharmacology of Sutherlandia frutescens (Fabaceae), " Journal of Ethnopharmacology, vol. 119, no. 3, pp. 620-629, 2008.
178. X. Fu, X.-C. Li, T. J. Smillie et al., "Cycloartane glycosides from Sutherlandia frutescens, " Journal ofNatural Products, vol. 71, no. 10, pp. 1749-1753, 2008.
179. X. Fu, X.-C. Li, Y.-H.Wang et al., "Flavonol glycosides from the South African medicinal plant Sutherlandia frutescens, " Planta Medica, vol. 76, no. 2, pp. 178-181, 2010.
180. J. Tai, S. Cheung, E. Chan, and D. Hasman, "In vitro culture studies of Sutherlandia frutescens on human tumor cell lines, " Journal of Ethnopharmacology, vol. 93, no. 1, pp. 9-19, 2004.
181. C. Vorster, A. Stander, and A. Joubert, "Differential signaling involved in Sutherlandia frutescens-induced cell death inMCF- 7 andMCF-12A cells, " Journal of Ethnopharmacology, vol. 140, no. 1, pp. 123-130, 2012.
182. T. V. Mqoco, M. H. Visagie, C. Albrecht, and A. M. Joubert, "Differential cellular interaction of Sutherlandia frutescens extracts on tumorigenic and non-tumorigenic breast cells, " South African Journal of Botany, vol. 90, pp. 59-67, 2014.
183. Y. Lu, N. Starkey, W. Lei et al., "Inhibition of hedgehog-signaling driven genes in prostate cancer cells by Sutherlandia frutescens extract, " PLoS ONE, vol. 10, no. 12, Article ID e0145507, 2015.
184. G. Leisching, B. Loos, T. Nell, and A.-M. Engelbrecht, "Sutherlandia frutescens treatment induces apoptosis and modulates the PI3-kinase pathway in colon cancer cells, " South African Journal of Botany, vol. 100, pp. 20-26, 2015.
185. P. S. Fasinu, H. Gutmann, H. Schiller, A.-D. James, P. J. Bouic, and B. Rosenkranz, "The potential of sutherlandia frutescens for herb-drug interaction, " Drug Metabolism and Disposition, vol. 41, no. 2, pp. 488-497, 2013.
186. P. Limtrakul, O. Khantamat, and K. Pintha, "Inhibition of P-glycoprotein function and expression by kaempferol and quercetin, " Journal of Chemotherapy, vol. 17, no. 1, pp. 86-95, 2005.
187. A. C.Muller, M. F. Skinner, and I. Kanfer, "Effect of the African traditional medicine, Sutherlandia frutescens, on the bioavailability of the antiretroviral protease inhibitor, atazanavir, " Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID324618, 6 pages, 2013.
188. M. Minocha, N. K. Mandava, D. Kwatra et al., "Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats, " International Journal of Pharmaceutics, vol. 413, no. 1-2, pp. 44-50, 2011.
189. M.Moudi, R. Go, C. Y. S. Yien, and M. Nazre, "Vinca alkaloids, " International Journal of Preventive Medicine, vol. 4, no. 11, pp. 1231-1235, 2013.
190. H. Quan, Y. Xu, L. Hu, and L. Lou, "Abstract 2053: F-XA7, a novel derivative of vinca alkaloidwith potent antitumor activity, efficiently overrides P-glycoprotein-mediated drug resistance both in vitro and in vivo, " Cancer Research, vol. 73, no. 8, supplement, p. 2053, 2013.
191. R. Mittra, E. M. Coyle, and R. Callaghan, "Just how and where does P-glycoprotein bind all those drugs?" in ABC Transporters-40 Years on, pp. 153-194, Springer, Berlin, Germany, 2016.
192. P. Limtrakul, O. Khantamat, and K. Pintha, "Inhibition of Pglycoprotein activity and reversal of cancermultidrug resistance by Momordica charantia extract, " Cancer Chemotherapy and Pharmacology, vol. 54, no. 6, pp. 525-530, 2004.
193. Q. Mi, B. Cui, G. L. Silva et al., "Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype, " Cancer Research, vol. 61, no. 10, pp. 4030-4037, 2001.
194. N. F. Smith, S. Mani, E.G. Schuetz et al., "Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2, " Annals of Pharmacotherapy, vol. 44, no. 11, pp. 1709-1717, 2010.
195. S. E. Drewes, E. Elliot, F. Khan, J. T. B. Dhlamini, and M. S. S. Gcumisa, "Hypoxis hemerocallidea-not merely a cure for benign prostate hyperplasia, " Journal of Ethnopharmacology, vol. 119, no. 3, pp. 593-598, 2008.
196. J. Watt and M. Breyer Brandwijk, Medicinal and Poisonous Plants of Southern and Eastern Africa, E. & S. Livingstone Ltd, Edinburgh, UK, 2nd edition, S. & E. Africa.[At Museum.] Review article General article, Drug plants Medicinal plants PharmacognosyMateria medica, Toxic plants Poisonous plants, geog, 1962.
197. C. Albrecht, "Hypoxoside: a putative prodrug for the treatment of malignancies, HIV infections, and inflammatory conditions, " South African Medical Journal, vol. 85, pp. 302-307, 1995.
198. A. Hutchings, A. H. Scott, G. Lewis, and A. Cunningham, Zulu Medicinal Plants: An Inventory, University of Kwazulu Natal Press, 1996.
199. B.-E. Van Wyk and N. Gericke, People's Plants: A Guide to Useful Plants of Southern Africa, Briza Publications, Pretoria, South Africa, 2000.
200. M. J. Van Der Merwe, K. Jenkins, E. Theron, and B. J. Van Der Walt, "Interaction of the di-catechols rooperol and nordihydroguaiaretic acid with oxidative systems in the human blood: a structure-activity relationship, " Biochemical Pharmacology, vol. 45, no. 2, pp. 303-311, 1993.
201. C. F. Albrecht, E. J. Theron, and P. B. Kruger, "Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy, " South AfricanMedical Journal, vol. 85, no. 9, pp. 853-860, 1995.
202. G. J. Boukes, The in vitro biological activities of three Hypoxis species and their active compounds [Ph.D. thesis], 2010.
203. P. S. Fasinu, H. Gutmann, H. Schiller, P. J. Bouic, and B. Rosenkranz, "The potential of Hypoxis hemerocallidea for herbdrug interaction, " Pharmaceutical Biology, vol. 51, no. 12, pp. 1499-1507, 2013.
204. Y. Naritomi, S. Terashita, and A. Kagayama, "Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate, " Xenobiotica, vol. 34, no. 5, pp. 415-427, 2004.
205. A. J. Scheen, "Pharmacokinetic interactions with thiazolidinediones, " Clinical Pharmacokinetics, vol. 46, no. 1, pp. 1-12, 2007.
206. D. A. Flockhart and J. E. Tanus-Santos, "Implications of cytochrome P450 interactions when prescribingmedication for hypertension, " Archives of Internal Medicine, vol. 162, no. 4, pp. 405-412, 2002.
207. T. Takanohashi, S. Kubo, A. Nakayama, R. Mihara, and M. Hayashi, "Inhibition of human liver microsomal CYP by nateglinide, " Journal of Pharmacy and Pharmacology, vol. 62, no. 5, pp. 592-597, 2010.
208. S.-M. He, A.-K. Yang, X.-T. Li, Y.-M. Du, and S.-F. Zhou, "Effects of herbal products on the metabolism and transport of anticancer agents, " Expert Opinion on Drug Metabolism & Toxicology, vol. 6, no. 10, pp. 1195-1213, 2010.
209. S. J. Baldwin, S. E. Clarke, and R. J. Chenery, "Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone, " British Journal of Clinical Pharmacology, vol. 48, no. 3, pp. 424-432, 1999.
210. D. F. V. Lewis, "Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families, " CurrentMedicinal Chemistry, vol. 10, no. 19, pp. 1955-1972, 2003.
211. T. Lynch and A. Price, "The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects, " American Family Physician, vol. 76, no. 3, pp. 391-396, 2007.
212. A. Scomparin, S. Salmaso, A. Eldar-Boock et al., "A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index, " Journal of Controlled Release, vol. 208, pp. 106-120, 2015.
213. S. Sharad, M. Patel, M. Bhuch, M. Chatterjee, and S. Shrivastava, "Regulatory status of traditional medicines in Africa Region, " International Journal of Research in Ayurveda and Pharmacy, vol. 2, no. 1, pp. 103-110, 2011.